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journa l homepage : www.e lsev ier . com/ loca te / rmedLETTER TO THE EDITORResponse to Leiro et al.We are very grateful for the comments to our article1
regarding the choice of sampling techniques for visible
lesions. The comments focus on the fact that we did not
take in to account the appearance of the endobronchial
lesions. Endobronchial visible lesions have a higher diag-
nostic yield than constriction and compression.2 There has
been some disagreement as how to classify visible lesions.
Dasgupta et al.3 includes constriction and compression in
visible lesions, while Jones et al.4 only includes exophytic
and submucosal lesions. We excluded constriction and
compression, but we were not able to distinguish between
exophytic and submucosal lesions due to the retrospective
nature of our study.
The primary aim of our study was to build a model for
evaluating different combinations of sampling techniques
in bronchoscopy. A cost-effectiveness analysis compares
the increase in cost to the increase in effectiveness. Two
previous papers have presented cost-effectiveness analyses
in bronchoscopy. Govert et al.5 performed a cost-effec-
tiveness analysis with quality-reduced days as an end point.
Van der Drift et al.6 wrote about cost-effectiveness of
endobronchial washing, but performed a cost minimization
analysis where only the costs of different strategies are
compared. We presented a cost-effectiveness analysis in
ERS, Berlin, 2008. Our end point was the diagnostic yield,
though the use of this end point in a cost-effectiveness
study is controversial. The willingness to pay for one addi-
tional positive sample was calculated based on the cost of
the delay and the cost of the diagnostic procedure that had
to be repeated to get the diagnosis.
When all patients get the diagnosis, a cost minimization
analysis is suggested to be more appropriate. The costs of
different strategies are compared to find the strategy that
is cheapest. Sensitivity analyses can be performed to find
the threshold values for all costs and all diagnostic yields.
There has been a discussion about the use of cost minimi-
zation analyses.7 A cost-effectiveness analysis is prefer-
able, but we need a common end point. We would like
others opinions on the possibility to use the diagnostic yield
as the end point in clinical cost-effectiveness studies of
diagnostic methods.DOI of original article: 10.1016/j.rmed.2009.09.024.
0954-6111/$ - see front matter ª 2010 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2010.04.020In your letter you say that your opinion about the most
cost effective strategy is EBNA for submucosal lesions. You
might be right, but we think that the use of the phrase
“cost effective strategy” should only be used when an
actual cost-effectiveness analysis has been performed.
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